Navigation Links
SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
Date:10/24/2008

FLAGSTAFF, Ariz., Oct. 24 /PRNewswire/ -- SenesTech, Inc. has initiated field trials of its platform technology on the Indonesian island of Java in continuing research collaboration with international partners.

After meeting with Dr. Grant Singleton of the International Rice Research Institute in Manila, Philippines, Drs. Loretta Mayer and Cheryl Dyer of SenesTech, Inc. will join Dr. Lyn Hinds of the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) and Dr. Sudarmaji of the Indonesian Rice Research Council (IRRC) at the field testing site of the IRRC in Sukamundi, Java. The group will initiate the first field trials of the active ingredient in ContraPest(R). This 21st century alternative to rat poison will be used to cause permanent reproductive failure in female rice field rats (Rattus argentiventer).

The environmentally neutral active ingredient in ContraPest(R) targets the ovaries of female rats, and selectively destroys early-stage egg cells. When these cells become inactive after exposure to ContraPest(R), they cannot mature, the animal can no longer ovulate, and the effect on rodent pest populations can be dramatic. These rodent pests can eat or damage up to 50% of a rice crop in Southeast Asia. Just a 10% increase in crop yield due to less rodent damage will result in feeding up to 380 million more people per year.

"Field testing in the agricultural environment where ContraPest(R) will be applied is a significant step forward in our product development process," said Everett Hale, CEO of SenesTech, Inc. "Collecting data from the rice fields on our first target species gives us the right information to design the best product possible."

Field trials with the rice fields on Java coincide with the annual rice planting and harvesting cycles. SenesTech, Inc. and its partners are planning more field testing in March and April 2009.

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.SenesTech.com. ContraPest(TM) is projected to be available for commercial use in the spring of 2010.

ABOUT:(SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona specializing in fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
2. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
3. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
4. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
8. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
11. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):